Drug Trial Radar · NCT01406548
Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density
Last checked: Nov 19, 2026Latest source record: Sep 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
Jul 2011
Primary completion
Oct 2013
Study completion Oct 2013
Sponsor
- Lead sponsor
- Ultragenyx Pharmaceutical IncIndustry
- Sponsor type
- Industry
- Collaborators
- Mereo BioPharma; Novartis
- First posted
- Aug 1, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 45 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to provide information on the safety, tolerability, pharmacokinetics (PK) and bone biomarker response following multiple BPS804 administration in multiple dosing regimens. This information will permit a comparison of the possible risks and benefits of different dosing regimens of the study drug to enable optimal doses and dose intervals to be tested in subsequent studies.
Conditions
- Osteopenia
- Osteoporosis
Interventions
BPS804 20mg/KgDrug
Placebo to 20mg/Kg BPS804Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline to month 9 in bone mineral density at the lumbar spine for the individual BPS804 groups and pooled placebo arms.Time frame: 9 months
- The number (percent) of subjects experiencing adverse events or serious adverse eventsTime frame: 9 months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Anaheim, California
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Berlin, New Jersey
Novartis Investigative Site
Duncansville, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.